Showing results (151-160 of 245) with videos related to
Sort By:
Pageof 25
Cancer Cell|August 14, 2014
Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressorGang Lu, Qing Zhang, Ying Huang, et al.Cancer Discovery|February 6, 2015
Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and TumorigenesisAndrea Lunardi, Shohreh Varmeh, Ming Chen, et al.Plos Genetics|August 6, 2016
Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma DevelopmentKrinio Giannikou, Izabela A Malinowska, Trevor J Pugh, et al.Cancer Research|November 23, 2021
Plasticity in the Absence of NOTCH Uncovers a RUNX2-Dependent Pathway in Small Cell Lung CancerDeli Hong, Erik H Knelson, Yixiang Li, et al.Cancer|April 30, 2009
Innovations and challenges in renal cancer: summary statement from the Third Cambridge ConferenceMichael B Atkins, Ronald M Bukowski, Bernard J Escudier, et al.Proceedings of the National Academy of Sciences of the United States of America|April 4, 2018
Autochthonous tumors driven by Rb1 loss have an ongoing requirement for the RBP2 histone demethylaseSamuel K McBrayer, Benjamin A Olenchock, Gabriel J DiNatale, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2014
Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlatesToni K Choueiri, Susanna Jacobus, Joaquim Bellmunt, et al.Molecular Cancer Research : MCR|February 2, 2022
Blocking PI3K p110β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate CancerXueliang Gao, Yubao Wang, Caroline F Ribeiro, et al.JCO Precision Oncology|February 16, 2022
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell CarcinomaBradley A McGregor, Wanling Xie, Elio Adib, et al.Nature Genetics|June 4, 2013
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancerAndrea Lunardi, Ugo Ala, Mirjam T Epping, et al.Pageof 25